In a Detroit Crain's article, Jan 28, 2018 9:44 pm, Tom Henderson reported that Sean Ainsworth is heading up Immusoft Corp., as their new CEO. Immusoft produces RST-001 which is an exciting technology and is hoped to "use a patient's immune cells to treat diseases." Read all about it. RetroSence was sold to Allergan in 2016 for around $60 million. Sean successfully completed NEF coaching in April of 2010.